Dr. Daniela Crisu

• 1988 - absolventa a Liceului “Emil Racovita” Iasi, profil fizica-chimie
• 1996 - licentiata a Facultatii de Medicina Generala din cadrul Universitatii de Medicina si Farmacie “Gr.T.Popa” Iasi

Lucrari stiintifice:
• “Studiu retrospective a 54 cazuri de pericardita lichidiana”- Revista Romana de Cardiologie vol.VIII, NR.2,1998
• “Valoarea monitorizarii continue a presiunii arteriale in aprecierea tratamentului antihipertensiv” – Al XXXVIII-lea Congres National de Cardiologie 1999
• “Tratamentul hipertensiunii arteriale esentiale cu inhibitori ai receptorilor de AT1”- Revista Romana de Cardiologie vol.XIII, NR.3,2000
• “Evaluarea eficacitatii Nitromint( aerosol ) in angina pectorala de efort”- Revista Romana de Cardiologie vol.XIII, NR.3, 2000
• “Corelatii electroecocardiografice in hipertrofia ventricolului stang”- Revista Romana de Cardiologie vol.XIV,nr.3, 2001
• “ Evaluarea riscului de aritmii ventriculare precoce post infarct miocardic acut”- Revista Romana de Cardiologie vol.XIX,nr.3, 2004
• “Tratamentul actual al pacientilor foarte varstnici (>75 ani) cu infarct miocardic acut: limite si progrese ”- Revista Romana de Cardiologie vol.XXI, suplimentul A , 2006
• “Who's who in insuficienta cardiaca acuta – caracteristici ale pacientilor cu diferite profiluri clinice”- Revista Romana de Cardiologie vol.XXII, suplimentul A , 2007.
• “Modificări electrocardiografice în diselectrolitemii” . Rev Rom Cardiol 2008; A: 37
• “Stratificarea riscului de deces intra-spitalicesc al pacientilor cu insuficienta cardiaca acuta: o estimare intr-adevar utila in practica? (The three nodes risk stratification of in-hospital mortality for patients with acute heart failure: this is really useful?)”. Revista Româna de Cardiologie 2008; XXIII (supliment A): A82-A83. (ISSN 1583-2996, recunoscuta CNCSIS categoria B, cod 379).
• „Thrombolysis for deep venous thrombosis between risk and efficacy”. Eur Heart J 2008; 29 (Abstract Supplement): 211 (FI 2008: 2.1)2009
• “Tratamentul trombolitic in tromboza venoasa profunda.Rezultate pe termen scurt si mediu”- Revista Romana de Cardiologie vol.XXIV, Nr.1, 2009
• „Tromboza venoasă profundă acută” – anticoagulare sau tromboliză? Rev Rom Cardiol 2009; vol XXIV (supl A): 78-79
• “Which features of the metabolic syndrome predict the severity and clinical outcome of angiographic peripheral arterial disease”. Eur Heart J 2010; 31 (Suppl 1): P5489 (FI 2010: 2.071)
• “Valoarea prognostica a nivelelor glicemiei de la internare versus externare la pacientii nondiabetici cu infarct miocardic acut (Prognostic implication of admission vs discharge glucose level in nondiabetic AMI patients)”. (rezumat). Revista Româna de Cardiologie 2009; XXIV (supliment A): A43-A44. (ISSN 1583-2996, recunoscuta CNCSIS categoria B, cod 379).
• “Stratificarea riscului de aritmii ventriculare maligne şi moarte subită cardiacă post infarct miocardic acut. Revista Medico-Chirurgicala.Volumul 114 (2010),Numarul 1
• Efecele aritmogene ale alcoolului. Krasniqi A, Bostaca I, Dima-Cosma C, Crişu D, Aursulesei V. Rev Med Chir Soc Med Nat Iasi. 2011 Oct-Dec;115(4):1052-6. PMID: 22276445 • The role of echocardiography and Tc-99m-HDP scintigraphy in non-invasive diagnosis of cardiac amyloidosis – A case series and literature review. Costache II, Buburuz AM, Crisu D, Statescu AM, Ungureanu C, Aursulesei V. Medicine (Baltimore) 2019; 98(38): e17256.

• The role of multimodality imaging in revealing a rare cause of persistent ascites. Buburuz AM, Marcu DTM, Demsa I, Tinica G, Petris A, Crisu D. Eur Heart J - Cardiovas Imaging 2020; 21(Supplement_1), pp.jez319-502.
• Transthyretin cardiac amyloidosis: a review of the nuclear imaging findings with emphasis on the radiotracers mechanisms.. Teodor M Ionescu , Wael Jalloul , Cati R Stolniceanu , Roxana Iacob , Laura P Grecu, Ana-Maria Stătescu , Irena Grierosu , Mihai Guțu , Adrian Gavrilescu , Crișu Daniela , Antoniu Petriș , Manuela Ciocoiu , Cristina Ungureanu , Cipriana Ștefănescu. . Ann Nucl Med. 2021 Sep;35(9):967-993. doi: 10.1007/s12149-021-01650-3.
• Large inferior vena cava tumor with cardiac extension revealed by venous thrombembolism in a patient with complete situs inversus: what are the odds?.Diana-Andreea Roscaneanu , Ovidiu Mitu, Daniela Crisu, Radu-Stefan Miftode, Mihai Stefan Cristian Haba, Antoniu Octavian Petris. Romanian Journal of Cardiology | Vol. 31, No. 1, 2021. • The importance of transesophageal echocardiography in the therapeutic approach of a patient with Hakim-Adams syndrome and right atrial mass. January 2020., Radu-Stefan Miftode, Daniela Crisu, Antoniu Octavian Petris. European Heart Journal Cardiovascular Imaging 21(Supplement_1).DOI:10.1093/ehjci/jez319.272.
• Thrombophilia: An Amalgam of Never Ending Clinical Manifestations. Stefania Teodora Duca, Florin Mitu, Andreea Timofte, Adriana Chetran, Monica Ureche, Daniela Crișu, Ovidiu Mitu , Alexandru Dan Costache ,Irina Iuliana Costache. Medicină internă 19(3):41-48, October 2022.
• Role of Diphosphonates Bone Scintigraphy in Correlation with Biomarkers for a Personalized Approach to ATTR Cardiac Amyloidosis in North-Eastern Romania. Teodor Marian Ionescu, Manuela Ciocoiu , Raoul-Vasile Lupusoru , , Irena Grierosu ,Radu Andy Sascău , Wael Jalloul , Roxana Iacob , Cati Raluca Stolniceanu , Alexandra Clement ,Ana-Maria Stătescu , Daniela Crisu , Antoniu Octavian Petris, Florin Mitu, Cipriana Stefănescu. Diagnostics 13(1):83. December 2022. DOI: 10.3390/diagnostics13010083 

Carti publicate:
1. Chioncel O, Vinereanu D, Ionescu DD, Datcu M, Dorobantu M, Bruckner I, Capâlneanu R, Vintila M, Cristodorescu R, Darabantiu D, Giuca A, Gurghean A, Grigorica L, Fruntelata A, Protopopescu L, Ochean V, Ott D, Vladoianu M, Serban A, Aursulesei V, Crisu D, Petris A, Bengus M, Mihailescu O, Istrate C, Cochino E, Macarie C. Registrul român de insuficienta cardiaca acuta - premize, obiective, metodologie. Media Med Publicis, Bucuresti, 2008: 289-309 ISSN 1843-3731.
2.Chioncel O, Vinereanu D, Ionescu DD, Datcu, MD, Dorobantu M, Brukner I, Capalneanu R, Cristodorescu R, Darabantiu D, Giuna A, Gurghean A,Grigorica L, Fruntelata A, Vintila M, Protopopescu L, Ochean V, Ott D, Vladoianu M, Serban A, Aursulesei V, Crisu D, Petris A, Bengus M, Mihailecu O, Istrate C, Florian A, Cochino E, Macarie C. Caracteristici clinice si de prognostic la pacientii cu soc cardiogen din Registrul Roman de Insuficienta cardiaca acuta (RRICA). Progrese in cardiologie 2010. Ed. T3 Info, Bucuresti 2010: 225-234. ISSN 1843-3731. (editura acreditata CNCSIS cod 302).
3.Coautor la cartea “Confruntari clinice. Cazuri comentate” , Editura Junimea , Iasi, 2003.
4.Coautor la cartea “Controverse si erori de diagnostic in cardiologie”, Editura Junimea , Iasi, 2006.
5.”Noi perspective terapeutice in insuficienta cardiaca: antagonistii receptorilor de vasopresina. Progrese in cardiologie 2011”. Ed. T3 Info, Bucuresti 2010: 390-402. ISSN 1843-3731. (editura acreditata CNCSIS cod 302).
6.Coautor la cartea Tromboza și antitromboza. Sub redacţia Antoniu Petriș, Editura PIM, 2018, ISBN 978-606-13-4517-5.
7.Coautor la BIOFACTORII în patologia umană .Viața Medicală, Editura MEDICHUB MEDIA, București, 2020.

Investigator principal in urmatoarele studii internationale:
1. Clinical Trial 502.550 (A randomised, double-blind, double dummy, active controlled, parallel group, forced titration study to compare the fixed-dose combination of Telmisartan 80mg plus Hydrochlorothiazide 25mg (T80/HCTZ25) versus Telmisartan 80mg (T80) monotherapy as first line therapy in patients with grade 2 or grade 3 hypertension) Protocol 502.550 ; Phase 4; 2009-2010;
2. ENGAGE –AF TIMI 48 (A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of Edoxaban (DU-176b) Versus Warfarin In Subjects With Atrial Fibrillation - Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation) Protocol DU176b-C-U301 ; Phase 3;2008-2013;
3. PEGASUS TIMI 54 (The Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin ) Protocol D5132C00001; Phase 3;2010-2014;
4. M13-377 ( A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease) Protocol M13-377; Phase 3;2012-2013;
5. ATMOSPHERE (Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure) Protocol CSPP100F2301; Phase 3;2009-2015; 6. SIGNIFY (Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure. A Randomised Double-blind Placebo-controlled International Multicenter Study. Study Assessing the Morbi-mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease) Protocol CL3-16257-083; Phase 3;2009-2014;
7. Safety and efficacy of fixed dose combination of Indapamide SR 1.5mg / Amlodipine versus Valsartan / Amlodipine over 12-week of treatment with conditional titration based on the blood pressure control, in patients with uncontrolled essential hypertension after 1 month of Amlodipine 5 mg run-in treatment. An international, randomized, double-blind, multicenter controlled study.” Protocol Number CL3-05520-006; Phase 3;2013-2015;
8. AFFILIATE ( A Multinational, Multicenter Study To Assess The Effects Of Oral Sildenafil On Mortality In Adults With Pulmonary Arterial Hypertension (Pah) Protocol Number A1481324 ; Phase 3;2014- in derulare; 9. ATPCI study (The efficAcy and safety of Trimetazidine in Patients with angina pectoris having been treated by percutaneous Coronary Intervention. ATPCI study An international, multicentre, randomised, double-blind, placebo-controlled study in patients treated for 2 to 4 years). Protocol Number CL3-06790-010; Phase 3;2013- in derulare; 10. COMMANDER HF (A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure0 Protocol Number RIVAROXHFA3001; Phase 3;2013- in derulare; 11. MARINER (Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk) Protocol Number RIVAROXDVT3002 ; Phase 3;2014 - in derulare;
12. ENSURE-AF (A Prospective, Randomized, Open-Label Blinded Endpont Evaluation (PROBE) Parallel Group Study Comparing Edoxaban (DU-176b) With Enoxaparin/Warfarin Followed by Warfarin Alone in Subjects Undergoing Planned
Electrical Cardioversion of Nonvalvular Atrial Fibrillation) Protocol DU176b-F-E308 ; Phase 3;2014 -2016;
13. Efficacy of ranolazine in patients with Coronary Artery Disease (CAD). double-blind, randomised, multicenter, international, parallel group versus placebo. Protocol MEIN/10/Ran-Cad/003 Phase 4;2011 -2015. 14. FER-CARS-06 Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency 2018.

Coinvestigator la urmatoarele studii internationale:
1. EPHESUS Trial (A double-blind, randomized, placebo-controlled trial evaluation the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infarction) Protocol IE3-99-02-035 (investigator principal prof. dr. M.D. Datcu) 1999-2002;
2. EPLA Trial (Open-label extension study evaluating the safety of eplerenone in patients with heart failure) Protocol EPLA0501076 (investigator principal prof. dr. M.D. Datcu) 2003-2006;
3. PREVENT Trial (Prophylaxis of venous thromboembolism in patients with acute medical conditions requiring prolonged immobilization: a comparison of dalteparin (Fragmin) 5000 IU vs. placebo in a double-blind, randomized, multicenter study) Protocol 524E-CVD-0042-033 (investigator principal prof. dr. M.D. Datcu) 2001-2002; 4. BEAUTIFUL Trial (A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction ). Protocol CL3-16257-056 (investigator principal prof. dr. M.D. Datcu) 2004-2008; 5. SHIFT Trial (Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction) Protocol CL3-16257-063 (investigator principal prof. dr. M.D. Datcu) 2006-2010;
6. BALANCE (Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation ) Protocol CK-LX3401 (investigator principal prof. dr. M.D. Datcu) 2007-2010.
7. CA204-006 (A Phase 3, Randomised, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma)
8. IMCL CP12-0922 (A Study of Paclitaxel With or Without Ramucirumab in Metastatic Gastric Adenocarcinoma)
9. CT-P6 Clinical Trial (A randomized, double blind, parallel-group, Phase III Study to demonstrate equivalent efficacy and comperative safety of
CT-P6 with Herceptin, both in combination with Paclitaxel, in patients with metastatic breast cancer.
10. NETU-08-18 (A Phase III Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Study of the Efficacy and Safety of Oral Netupitant Administered in Combination With Palonosetron and Dexamethasone Compared to Oral Palonosetron and Dexamethasone for the Prevention of Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy)
11. SYR-322-402 (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome)
12. CL3-00780-150 (International follow-up study, after the investigational drug exposure in diabetic patients previously included in the REGULATE trial)
13. EFC11319-ELIXA (A randomised, double blind, placebo controlled, multicenter study to evaluate cardiovascular outcomes during treatment with lixisenatide in type 2 diabetes mellitis patients after an acute coronary syndrome event)